Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

A multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who are randomly assigned to receive 20 mg of atorvastatin per day or matching placebo is presented. The finding indicate that atorvastatin has no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infraction, and stroke in patients with diabetes receiving hemodialysis.